Maravai LifeSciences (MRVI) to Release Earnings on Thursday

Maravai LifeSciences (NASDAQ:MRVI) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Maravai LifeSciences to post earnings of ($0.0435) per share and revenue of $48.6730 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The business had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%. On average, analysts expect Maravai LifeSciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Maravai LifeSciences Stock Up 0.2%

Shares of NASDAQ:MRVI opened at $6.43 on Wednesday. Maravai LifeSciences has a fifty-two week low of $1.99 and a fifty-two week high of $7.44. The firm’s 50 day moving average price is $5.88 and its 200 day moving average price is $4.33. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -9.06 and a beta of 0.63.

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the sale, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. This represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

A number of large investors have recently bought and sold shares of MRVI. Quantessence Capital LLC purchased a new position in Maravai LifeSciences during the third quarter worth about $31,000. CIBC Bancorp USA Inc. acquired a new position in Maravai LifeSciences during the 3rd quarter worth approximately $33,000. Abel Hall LLC acquired a new position in Maravai LifeSciences during the 3rd quarter worth approximately $33,000. Insigneo Advisory Services LLC purchased a new position in shares of Maravai LifeSciences during the 4th quarter worth approximately $34,000. Finally, Virtu Financial LLC purchased a new position in shares of Maravai LifeSciences during the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Analyst Ratings Changes

MRVI has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. Wall Street Zen lowered Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday. Wells Fargo & Company boosted their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Finally, UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $5.50.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.